Patents Examined by Bo Peng
  • Patent number: 8309697
    Abstract: The invention provides novel TRIM polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length TRIM proteins, the invention further provides isolated TRIM fusion proteins, antigenic peptides and anti-TRIM antibodies. The invention also provides TRIM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an TRIM gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of viral infection and/or replication, e.g., HIV infection. The invention further provides methods for identifying a compound capable of treating or preventing viral infection and/or replication, e.g., HIV infection and AIDS. In addition, the invention provides a method for treating a subject having a viral infection and/or replication, e.g.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: November 13, 2012
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Joseph Sodroski, Matthew Stremlau, Christopher M. Owens
  • Patent number: 8298820
    Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: October 30, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B Weiner, Jian Yan, Matthew P Morrow
  • Patent number: 8282932
    Abstract: Disclosed are split-core carrier substance which, as separate polypeptide, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule against which an immune response is to be induced. According to the invention, the foreign molecule, especially the heterologous foreign amino acid sequence, is fused to the C terminus or the core N domain or to the N terminus of the core C domain and the core protein can form capsid-like particles. The invention also relates to the associated production method.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: October 9, 2012
    Assignee: Universitatsklinikum Freiburg
    Inventors: Michael Nassal, Claudia Skamel, Andreas Walker
  • Patent number: 8278093
    Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: October 2, 2012
    Assignee: Vical Incorporated
    Inventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
  • Patent number: 8268323
    Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 18, 2012
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.
    Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
  • Patent number: 8246957
    Abstract: Disclosed are monoclonal antibodies and antibody fragments which recognize antigens encoded by HERV DNA sequences, and methods for production, including recombinant antibody fragments derived from lymphoid cells of lupus patients that make antibodies which neutralize HIV.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: August 21, 2012
    Inventor: Sudhir Paul
  • Patent number: 8236558
    Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: August 7, 2012
    Assignee: Novartis AG
    Inventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
  • Patent number: 8227243
    Abstract: Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: July 24, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
  • Patent number: 8221762
    Abstract: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: July 17, 2012
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gregory A. Poland, Inna G. Ovsyannikova, David C. Muddiman, Kenneth L. Johnson
  • Patent number: 8216834
    Abstract: The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: July 10, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SPA
    Inventors: Stefano Colloca, Alfredo Nicosia, Elisabetta Sporeno, Paolo Palazzolo, legal representative, Agostino Cirillo, Bruno Bruni Ercole, Annalisa Meola
  • Patent number: 8211443
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: July 3, 2012
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Patent number: 8197819
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 12, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Patent number: 8192927
    Abstract: The present invention relates to binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. The disclosure provides nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H5N1 infection. In a preferred embodiment, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9 and H1-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: June 5, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
  • Patent number: 8183352
    Abstract: The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: May 22, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Velpandi Ayyavoo, Thanadavarayan Nagashunmugam, David B. Weiner
  • Patent number: 8182985
    Abstract: The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101 antibodies.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: May 22, 2012
    Assignee: Functional Genetics, Inc.
    Inventor: Limin Li
  • Patent number: 8178657
    Abstract: The present invention relates to a polypeptide having a sequence of 7 to 20 amino acid residues, which is capable of modulating the immunosuppressive properties of a viral protein or a fragment thereof, against the host in which it is expressed (immunosuppression-modulatory sequence) when it substitutes the homologous sequence of the viral protein or fragment, the polypeptide including the minimum following consensus amino acid sequence: X1Y9Y10Y11CY12X2 wherein, X1 and X2 are selected to impact on the immunosuppressive properties, and Y9 to Y12 represent variable amino acid residues.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: May 15, 2012
    Assignees: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XI
    Inventors: Martial Renard, Marianne Mangeney, Thierry Heidmann
  • Patent number: 8173375
    Abstract: Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David Ying Chien, Yiu-Lian Fong, Azita Tabrizi, Heather Todd, Mark David VanCleve
  • Patent number: 8168190
    Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: May 1, 2012
    Assignee: Biogen Idec MA Inc.
    Inventor: Kenneth Murray
  • Patent number: 8133723
    Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: March 13, 2012
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Ruxandra Draghia-Akli, David B Weiner, Jian Yan, Dominick J Laddy
  • Patent number: 8124721
    Abstract: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with this peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: February 28, 2012
    Assignee: INIMEX Pharmaceuticals Inc.
    Inventors: Oreola Donini, Annett Rozek, Shannon Wayne Lentz